Intrinsic Therapeutics earned a Category 1 CPT code from the American Medical Association for bone anchored annular closure, according to an Oct. 24 news release.
It is the first CPT code that describes closing large annular defects using the company's Barricaid device.
"A new Category 1 CPT code represents a significant milestone for any new technology," spine surgeon Serena Hu, MD, said in the release. "Category 1 codes are intended to describe procedures that demonstrate high levels of clinical evidence and efficacy. Most importantly, this distinction demonstrates that Barricaid has met the rigorous criteria the AMA sets forth, including robust clinical data and widespread adoption by physicians, further substantiating the medical necessity of this critical therapeutic alternative."
Barricaid has been used in more than 11,000 patients and is desiged to prevent reheniation and reoperation in lumbar discectomy patients with large annular defects.